T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases

Cell Adhesion and Migration

Volumn 4, Issue 2, 2010, Pages 273-283

  Manolios, Nicholas ^a   Ali, Marina ^a   Bender, Vera ^a  

^a NONE

Author keywords

Biophysics; Peptides; Therapeutics; Transmembrane

Indexed keywords

ADJUVANT; AMINO ACID; AMINO ACID DERIVATIVE; CARBOHYDRATE; CORE PEPTIDE; CORE PEPTIDE COMPLEMENTARY DNA; CORTICOSTEROID; CYCLOSPORIN; GLUCOSE DERIVATIVE; GLUCOSE SUCCINIC ACID; LIPID; MEMBRANE PROTEIN; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT DNA; SPHINGOLIPID; SUGAR; T LYMPHOCYTE RECEPTOR; TRIPALMITIN; TROMETAMOL; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOPHYSICS; CELL SPECIFICITY; CLINICAL RESEARCH; COMPLEX FORMATION; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DIMERIZATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; ELECTRON MICROSCOPY; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATION; LIPID MEMBRANE; LIPID RAFT; MYRISTYLATION; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OLIGOMERIZATION; PROTEIN ASSEMBLY; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR POTENTIAL; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; T LYMPHOCYTE; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE; CHEMISTRY; GENETICS; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; CELL MEMBRANE; HUMANS; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL;

EID: 77953553255     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.2.11909     Document Type: Review

References (101)

1. Engelman DM. Membranes are more mosaic than fluid. Nature 2005; 438:578-80.
2. McLaughlin S, Murray D. Plasma membrane phosphoinositide organization by protein electrostatics. Nature 2005; 438:605-11.
3. Phillips R, Ursell T, Wiggins P, Sens P. Emerging roles for lipids in shaping membrane-protein function. Nature 2009; 459:379-85.
4. Bowie JU. Solving the membrane protein folding problem. Nature 2005; 438:581-9.
5. White SH. Biophysical dissection of membrane proteins. Nature 2009; 459:344-6.
6. Maggio R, Vogel Z, Wess J. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc Natl Acad Sci USA 1993; 90:3103-7.
7. Walters RFS, DeGrado WF. Helix paking motifs in membrane proteins. PNAS 2006; 103:13658-63.
8. Lemmon M, JM F, Treutlein H, Zhang J, Engleman D. Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry 1992; 31:12719-25.
9. Senes A, Engle DE, DeGRado WF. Folding of helical membrane proteins: the role of polar, GxxxG-like and proline motifs. Curr Opin Struct Biol 2004; 14:465-79.
10. Sal-Man N, Gerber D, Shai Y. The identification of a minimal dimerisation motif QXXS that enales homo- and hetero-association of transmembrane helies in vivo. J Biol Chem 2005; 280:27449-57.
11. Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, et al. Computational design of peptides that target transmembrane helices. Science 2007; 315:1817-22.
12. Ng GYK, O'Dowd BF, Lee SP, Chung HT, Brann MR, Seeman P, et al. Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 1996; 227:200-4.
13. Wells J, McClendon C. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450:1001-9.
14. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors Nature 2009; 459:356-63.
15. Herbert TE, Moffett S, Morello J-P, Loisel TP, Bichet DG, Barret C, et al. A Peptide derived from a b2-adrenergic receptor transmembrane domain inhibits both receptor dimerisation and activation. J Biol Chem 1996; 271:16384-92.
16. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GYK, et al. A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerisation. J Biol Chem 1998; 273:30244-8.
17. George SR, Ng GYK, Lee SP, Fan T, Varghese G, Wang C, et al. Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: Novel strategy for functional inhibition of membrane proteins in vivo. J Pharmacol Exp Ther 2003; 307:481-9.
18. Jimonet P, Jäger R. Strategies for designing GPCR-focused libraries and screening sets. Curr Opin Drug Discov Devel 2004; 7:325-33. (Pubitemid 44111942)
19. Panetta R, Greenwood M. Physiological relevance of GPCR oligomerization and its impact on drug discovery. Drug Discov Today 2008; 13:1059-66.
20. Dalrymple M, Pfleger K, Eidne K. G protein-coupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol Ther 2008; 118:359-71.
21. Heilker R, Wolff M, Tautermann C, Bieler M. G-protein-coupled receptor-focused drug discovery using a target class platform approach. Drug Discov Today 2009; 14:231-40.
22. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
23. Kolibaba K, Druker B. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997; 1333:217-48.
24. Porter A, Vaillancourt R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17:1343-52. (Pubitemid 28458404)
25. Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 2004; 50:23-38.
26. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, et al. Transmembrane Peptides as Inhibitors of ErbB Receptor Signaling Mol Biol Cell 2004; 15:3464-74.
27. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-65.
28. Finger C, Escher C, Schneider D. The Single Transmembrane Domains of Human Receptor Tyrosine Kinases Encode Self-Interactions. Sci Signal 2009; 2:56.
29. Bennasroune A, Gardin A, Auzan C, Clauser E, Dirrig-Grosch S, Meira M, et al. Inhibition by transmembrane peptides of chimeric insulin receptors. Cell Mol Life Sci 2005; 62:1420-9071.
30. Senes A, Gerstein M, Engelman DM. Statistical Analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. J Mol Biol 2000; 296:921-36.
31. Roth L, Nasarre C, Dirrig-Grosch S, Aunis D, Crémel G, Hubert P, et al. Transmembrane Domain Interactions Control Biological Functions of Neuropilin-1. Mol Biol Cell 2008; 19:646-54.
32. Pan Q, Chanthery Y, Liang W, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11:53-67.
33. Miller L, Justen H, Scholmerich J, Straub R. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000; 14:2097-107.
34. Straub R, Grum F, Strauch U, Capellino S, Bataille F, Bleich A, et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut 2008; 57:911-21.
35. Lorton D, Lubahn C, Sweeney S, Major A, Lindquist CA, Schaller J, et al. Differences in the injury/sprouting response of splenic noradrenergic nerves in Lewis rats with adjuvant-induced arthritis compared with rats treated with 6-hydroxydopamine. Brain Behav Immun 2009; 23:276-85.
36. Fassold A, Falk W, Anders S, Hirsch T, Mirsky VM, Straub RH. Soluble Neuropilin-2, a Nerve Repellent Receptor, Is Increased in Rheumatoid Arthritis Synovium and Aggravates Sympathetic Fiber Repulsion and Arthritis. Arthritis Rheum 2009; 60:2892-901.
37. Luo B, Carman C, Springer T. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25:619-47.
38. Abram C, Lowell C. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 2009; 27:339-62.
39. Caputo GA, Litvinov RI, Li W, Bennett JS, DeGrado WF, Yin H. Computationally designed peptide inhibitors of protein-protein interactions in membranes. Biochemistry 2008; 47:8600-6.
40. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003; 24:640-7.
41. Yonekawa K, Harlan J. Targeting leukocyte integrins in human diseases. J Leukoc Biol 2005; 77:129-40.
42. Sigalov A. Multi-chain immune recognition receptors: spatial organization and signal transduction. Semin Immunol 2005; 17:51-64.
43. Feng J, Call ME, Wucherpfennig KW. The assembly of diverse immune receptors is focused on a polar membrane-embedded interaction site. PLOS Biol 2006; 4:142.
44. Call ME, Wucherpfennig KW. Molecular mechanisms for the assembly of the T-cell receptor-CD3 complex. Mol Immunol 2004; 40:1295-305.
45. Call ME, Wucherpfennig KW. The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol 2005; 23:101-25.
46. Alcover A, Mariuzza R, Ermonval M, Acuto O. Lysine 271 in the transmembrane domain of the T-cell antigen receptor beta chain is necessary for its assembly with the CD3 complex but not for alpha/beta dimerization. J Biol Chem 1990; 265:4131-5. (Pubitemid 120026803)
47. Bonifacino J, Cosson P, Klausner R. Co-localised transmembrane determinants for ER degradation and subunit assembly explain the intra-cellular fate of TCR chains. Cell 1990; 63:503-13. (Pubitemid 120034914)
48. Manolios N, Letourneur F, Bonifacino JS, Klausner RD. Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T cell antigen receptor. EMBO J 1991; 10:1643-51. (Pubitemid 21905630)
49. Manolios N, Li ZG. The T cell antigen receptor beta chain interacts with the extracellular domain of CD3-gamma. Immunol Cell Biol 1995; 73:532-6. (Pubitemid 26037498)
50. Manolios N, Kemp O, Li ZG. The T-cell antigen receptor alpha and beta chains interact via distinct regions with the CD3 chains. Eur JImmunol 1994; 24:84-92.
51. Manolios N. Hierachy of T cell antigen receptor assembly. Immunol Cell Biol 1995; 73:544-8. (Pubitemid 26037500)
52. Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions and the assembly of the T cell receptor complex. Science 1990; 249:274-7. (Pubitemid 20232085)
53. Manolios N, Collier S, Taylor J, Pollard J, Harrison L, Bender V. T-cell antigen receptor transmembrane peptides modulate T-cell function and T-cell mediated disease. Nat Med 1997; 3:84-7.
54. Gollner GP, Muller G, Alt R, Knop J, Enk AH. Therapeutic application of T cell receptor mimic peptides or cDNA in the treatment of T cell-mediated skin diseases. Gene Ther 2000; 7:1000-4. (Pubitemid 30398347)
55. Huynh NT. T cell antigen receptor transmembrane peptides and their effects on B and Natural Killer Cells. University of Sydney 2005.
56. Mahnke K, Qian Y, Knop J, Enk AH. Dendritic cells, engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo. Nat Biotechnol 2003; 21:903-8.
57. Gerber D, Quintana FJ, Bloch I, Cohen IR, Shai Y. D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J 2005; 19:1190-2.
58. Ali M, Amon M, Bender V, Manolios N. Hydrophobic transmembrane-peptide lipid conjugations enhance membrane binding and functional activity in T-cells. Bioconjug Chem 2005; 16:1556-63.
59. Amon MA, Ali M, Bender V, Chan Y-N, Toth I, Manolios N. Lipidation and Glycosylation of a T-cell Antigen Receptor (TCR) Transmembrane Hydrophobic Peptide Dramatically Enhances in vitro and in vivo Function. BBA-Mol Cell Res 2006; 1763:879-88.
60. Wells XE, Bender VJ, Francis CL, He-Williams HM, Manthey MK, Moghaddam MJ, et al. Tris and the ready production of drug-fatty acyl conjugates. Drug Dev Res 1999; 46:302-8.
61. McLaughlin S, Aderem A. The myristoyl-electrostatic switch: A modulator of reversible protein-membrane interactions. Trends Biochem Sci 1995; 20:272-6.
62. Bhatnagar RS, Gordon JI. Understanding covalent modifications of proteins by lipids: where cell biology and biophysics mingle. Trends cell Biol 1997; 7:14-20.
63. Blanchfield JT, Toth I. Modification of peptides and other drugs using lipoamino acids and sugars. Methods Mol Biol 2005; 298:45-61.
64. Bender V, Ali M, Amon M, Diefenbach E, Manolios N. T-cell antigen receptor peptide-lipid membrane interactions using Surface Plasmon Resonance. J Biol Chem 2004; 279:54002-7.
65. Ali M, De Planque M, Huynh N, Manolios N, Separovic F. Biophysical studies of transmembrane peptide derived from the T cell antigen receptor. Lett Peptide Sci 2002; 8:227-33.
66. Amon MA, Ali M, Bender V, Hall K, Aguilar M-I, Aldrich-Wright J, et al. Kinetic and conformational properties of a novel T-cell antigen receptor transmembrane peptide in model membranes. J Pept Sci 2008; 14:714-24.
67. Zheng G, Torres AM, Ali M, Manolios N, Price WS. NMR Study of the Structure and Self-Association of Core Peptide in Aqueous Solution and DPC Micelles. Biopolymers 2010; In press.
68. Bauer S, Groh V, Wu J, Steinle A, Phillips J, Lanier L, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9.
69. Braud V, Allan D, O'Callaghan C, Soderstrom K, D'Andrea A, Ogg G, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9.
70. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268:405-8.
71. Garcia K, Teyton L, Wilson I. Structural basis of T cell recognition. Annu Rev Immunol 1999; 17:369-97.
72. Monteiro R, Van De Winkel J. IgA Fc receptors. Annu Rev Immunol 2003; 21:177-204.
73. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati M, Vitale M, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995; 2:439-49.
74. Ali M, Salam NK, Amon MA, Bender V, Hibbs DE, Manolios N. T-cell antigen receptor - alpha chain transmembrane peptides: Correlation between structure and function. Int J Pept Res Ther 2006; 12:261-7.
75. Wang XM, Djordjevic JT, Bender V, Manolios N. T cell antigen receptor (TCR) transmembrane peptides colocalise with TCR, not lipid rafts, in surface membranes. Cell Immunol 2002; 215:12-9.
76. Wang XM, Djordjevic JT, Kurosaka N, Schibeci S, Lee L, Williamson P, et al. T-cell antigen receptor peptides inhibit signal transduction within the membrane bilayer. Clin Immunol 2002; 105:199.
77. Huynh NT, Ffrench RA, Boadle RA, Manolios N. Transmembrane TCR peptides inhibit B and NK cell function. Immunology 2003; 108:458-64.
78. Vandebona H, Ali M, Amon M, Bender V, Manolios N. Immunoreceptor transmembrane peptides and their effect on Natural Killer (NK) cell cytotoxicity. Protein Pept Lett 2006; 13:1017-24.
79. Sigalov A. Signaling Chain Homooligomerisation (SCHOOL) Model. Chapter 12. Multichain immune reognition receptor signaling: From spatiotemporal organization to human disease.
80. Zhang G, Lin X, Long Y, Wang Y, Zhang Y, Mi H, et al. A peptide fragment derived from the T-cell antigen receptor protein alpha-chain adopts beta-sheet structure and shows potent antimicrobial activity. Peptides 2009; 30:647-53.
81. Sigalov AB. Transmembrane interactions as immunotherapeutic targets: lessons from viral pathogenesis. Adv Exp Med Biol 2007; 601:335-44.
82. Arnon T, Achdout H, Levi O, Markel G, Saleh N, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6:515-23.
83. Sullivan BM, Coscoy L. Downregulation of the T-Cell Receptor Complex and Impairment of T-Cell Activation by Human Herpesvirus 6 U24 Protein. J Virol 2008; 82:602-8.
84. Min C, Bang S, Cho B, Choi Y, Yang J, Lee S, et al. Role of amphipathic helix of a herpesviral protein in membrane deformation and T cell receptor downregulation. PLoS Pathog 2008; 4:1000209.
85. Park J, Lee B, Choi J, Means R, Choe J, Jung JU. Herpesviral protein targets a cellular WD repeat endosomal protein to downregulate T lymphocyte receptor expression. Immunity 2002; 17:221-33.
86. Sigalov A. Novel mechanistic insights into viral modulation of immune receptor signaling. PLoS Pathog 2009; 5:1000404.
87. Huang C-c, Lam SN, Acharya P, Tang M, Xiang S-H, Shahzad-ul Hussan S, et al. Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4. Science 2007; 317:1930-4.
88. Kim JH, Hartley TL, Curran AR, Engelman D. Molecular dynamics studies of the transmembrane domain of gp41 from HIV-1. Biochima et Biophysica Acta 2009; 1788:1804-12.
89. Srinivas R, Mulligan M, Owens R, Srinivas S, Anantharamaiah G, Segrest J, et al. Inhibitors of human immunodeficiency virus-induced membrane fusion. Wiley-Liss, New York 1992.
90. Owens R, Tanner C, Mulligan M, Srinivas R, Compans R. Oligopeptide inhibitors of HIV-induced syncytium formation. Aids Res Hum Retroviruses 1990; 6:1289-96.
91. McPhee D, Cumming S, Pavuk N, Doherty R, Stapleton D, Kemp B. Petative contact region between HIV envelope proteins gp120 and gp41: antiviral action of synthetic peptide analogs. New York: Cold Spring Harbor Laboratory, Cold Spring Harbor 1989.
92. Miller M, Garry R, Jaynes J, Montelaro R. A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. Aids Res Hum Retroviruses 1991; 7:511-9.
93. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. Synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992; 89:10537-41.
94. LaBonte J, Lebbos J, Kirkpatrick P. Enfuvirtide. Nat Rev Drug Discov 2003; 2:345-6.
95. Pan C, Cai L, Lu H, Qi Z, Jiang S. Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains. J Virol 2009; 83:7862-72.
96. Wexler-Cohen Y, Shai Y. Membrane anchored HIV-1 heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog 2009; 5:1000509.
97. Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005; 115:2149-58.
98. Bloch I, Quintana FJ, Gerber D, Cohen T, Cohen IR, Shai Y. T-Cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J 2007; 21:393-401.
99. Sigalov AB. Signaling chain homooligomerization (SCHOOL) model. Adv Exp Med Biol 2008; 640:121-63.
100. Sigalov A. Signaling Chain Homooligomerisation (SCHOOL) Model. Chapter 20. Multichain immune reognition receptor signaling: From spatiotemporal organization to human disease.
101. Horejsi V, Zhang W, Schraven B. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat Rev Immunol 2004; 4:603-16.